Free Trial

BioCardia (BCDA) Competitors

BioCardia logo
$2.08 +0.08 (+4.00%)
Closing price 03:59 PM Eastern
Extended Trading
$2.09 +0.01 (+0.48%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCDA vs. PRLD, CELU, LIAN, ALGS, ABVC, ATNM, MURA, SCLX, GRCE, and STTK

Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Prelude Therapeutics (PRLD), Celularity (CELU), LianBio (LIAN), Aligos Therapeutics (ALGS), ABVC BioPharma (ABVC), Actinium Pharmaceuticals (ATNM), Mural Oncology (MURA), Scilex (SCLX), Grace Therapeutics (GRCE), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry.

BioCardia vs. Its Competitors

Prelude Therapeutics (NASDAQ:PRLD) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, BioCardia had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for Prelude Therapeutics. BioCardia's average media sentiment score of 1.36 beat Prelude Therapeutics' score of 0.63 indicating that BioCardia is being referred to more favorably in the news media.

Company Overall Sentiment
Prelude Therapeutics Positive
BioCardia Positive

Prelude Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 462.50%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 1,101.92%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Prelude Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prelude Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
BioCardia
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Prelude Therapeutics' return on equity of -89.18% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
Prelude TherapeuticsN/A -89.18% -69.26%
BioCardia N/A -30,792.60%-223.06%

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Comparatively, 20.0% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prelude Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

BioCardia has lower revenue, but higher earnings than Prelude Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude Therapeutics$7M6.45-$127.17M-$1.69-0.47
BioCardia$60K179.57-$7.95M-$2.33-0.89

Summary

Prelude Therapeutics beats BioCardia on 9 of the 16 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCDA vs. The Competition

MetricBioCardiaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.36M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-0.8921.3126.1719.90
Price / Sales179.57278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book11.567.518.055.38
Net Income-$7.95M-$55.05M$3.15B$248.50M
7 Day Performance-7.56%2.45%1.85%2.97%
1 Month Performance-7.96%7.33%4.81%6.02%
1 Year Performance-29.25%5.38%34.86%20.39%

BioCardia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCDA
BioCardia
3.7028 of 5 stars
$2.08
+4.0%
$25.00
+1,101.9%
-33.1%$10.36M$60K-0.8940Positive News
Insider Trade
PRLD
Prelude Therapeutics
3.2687 of 5 stars
$0.81
+3.1%
$4.50
+456.0%
-78.8%$44.34M$7M-0.48120
CELU
Celularity
0.1379 of 5 stars
$1.96
+5.9%
N/A-35.7%$44.31M$54.22M-0.74220News Coverage
Positive News
Gap Up
LIAN
LianBio
N/A$0.41
+1.2%
N/A+34.9%$44.31MN/A-0.51110
ALGS
Aligos Therapeutics
4.2166 of 5 stars
$7.21
flat
$70.00
+870.9%
-19.9%$44.08M$3.94M-0.4190Positive News
ABVC
ABVC BioPharma
0.3487 of 5 stars
$2.22
-14.3%
N/A+195.2%$43.98M$510K-17.0830High Trading Volume
ATNM
Actinium Pharmaceuticals
2.3337 of 5 stars
$1.40
-1.4%
$4.00
+185.7%
N/A$43.67M$81K-1.0130News Coverage
MURA
Mural Oncology
3.5399 of 5 stars
$2.47
-0.4%
$12.00
+385.8%
-19.6%$42.83MN/A-0.32119Positive News
SCLX
Scilex
2.152 of 5 stars
$5.89
-2.6%
$455.00
+7,625.0%
-90.8%$42.06M$56.59M-0.2080News Coverage
GRCE
Grace Therapeutics
2.1862 of 5 stars
$2.97
flat
$12.00
+304.0%
N/A$41.07MN/A-3.34N/APositive News
STTK
Shattuck Labs
3.3554 of 5 stars
$0.79
-7.3%
$7.50
+847.2%
-79.6%$40.89M$5.72M-0.57100News Coverage

Related Companies and Tools


This page (NASDAQ:BCDA) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners